| Neutrophils in cancer: prognostic role and therapeutic strategies A Ocana, C Nieto-Jiménez, A Pandiella, AJ Templeton Molecular cancer 16, 1-7, 2017 | 402 | 2017 |
| Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer MM Noblejas-López, C Nieto-Jimenez, M Burgos, M Gómez-Juárez, ... Journal of Experimental & Clinical Cancer Research 38, 1-9, 2019 | 76 | 2019 |
| Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer A Alcaraz-Sanabria, C Nieto-Jimenez, V Corrales-Sanchez, ... Molecular cancer therapeutics 16 (11), 2552-2562, 2017 | 47 | 2017 |
| Clinical considerations for the design of PROTACs in cancer C Nieto-Jiménez, EC Morafraile, C Alonso-Moreno, A Ocaña Molecular Cancer 21 (1), 67, 2022 | 45 | 2022 |
| Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome MM Noblejas-López, C Nieto-Jiménez, S Morcillo Garcia, J Pérez-Peña, ... OncoImmunology 8 (10), e1629780, 2019 | 41 | 2019 |
| Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome MM Noblejas-López, C Nieto-Jiménez, S Morcillo Garcia, J Pérez-Peña, ... OncoImmunology 8 (10), e1629780, 2019 | 41 | 2019 |
| Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome MM Noblejas-López, C Nieto-Jiménez, S Morcillo Garcia, J Pérez-Peña, ... OncoImmunology 8 (10), e1629780, 2019 | 41 | 2019 |
| Trastuzumab-targeted biodegradable nanoparticles for enhanced delivery of Dasatinib in HER2+ metastasic breast cancer E Niza, MM Noblejas-López, I Bravo, C Nieto-Jiménez, JA Castro-Osma, ... Nanomaterials 9 (12), 1793, 2019 | 38 | 2019 |
| BET inhibitors as novel therapeutic agents in breast cancer A Ocana, C Nieto-Jimenez, A Pandiella Oncotarget 8 (41), 71285, 2017 | 38 | 2017 |
| Poly (Cyclohexene Phthalate) Nanoparticles for Controlled Dasatinib Delivery in Breast Cancer Therapy E Niza, C Nieto-Jiménez, MM Noblejas-López, I Bravo, JA Castro-Osma, ... Nanomaterials 9 (9), 1208, 2019 | 25 | 2019 |
| Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors C Nieto-Jiménez, A Alcaraz-Sanabria, J Pérez-Peña, V Corrales-Sánchez, ... Oncotarget 8 (12), 19478, 2017 | 23 | 2017 |
| In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases A Ocaña, J Pérez-Peña, A Alcaraz-Sanabria, V Sánchez-Corrales, ... Oncotarget 7 (16), 22865, 2016 | 22 | 2016 |
| Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors S Morcillo-Garcia, MM Noblejas-Lopez, C Nieto-Jimenez, J Perez-Peña, ... PloS one 14 (4), e0209134, 2019 | 17 | 2019 |
| Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene M del Mar Noblejas-López, S Morcillo-García, C Nieto-Jiménez, ... PloS one 13 (11), e0207776, 2018 | 17 | 2018 |
| Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors J Pérez-Peña, A Alcaraz-Sanabria, C Nieto-Jiménez, R Páez, ... Oncotarget 8 (13), 21733, 2017 | 17 | 2017 |
| Mapping Bromodomains in breast cancer and association with clinical outcome J Pérez-Pena, R Páez, C Nieto-Jiménez, VC Sánchez, EM Galan-Moya, ... Scientific reports 9 (1), 5734, 2019 | 15 | 2019 |
| DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer C Nieto-Jiménez, A Alcaraz-Sanabria, R Páez, J Pérez-Peña, ... Oncotarget 8 (38), 62834, 2017 | 15 | 2017 |
| Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer C Nieto-Jimenez, EM Galan-Moya, V Corrales-Sanchez, ... Cancer Letters 491, 50-59, 2020 | 13 | 2020 |
| Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer L Serrano-Oviedo, M Nuncia-Cantarero, S Morcillo-Garcia, ... Cellular Oncology 43, 431-444, 2020 | 13 | 2020 |
| Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer V Corrales‐Sánchez, MM Noblejas‐López, C Nieto‐Jiménez, ... Journal of cellular and molecular medicine 24 (5), 3117-3127, 2020 | 12 | 2020 |
